Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 212.52 Billion KRW | 162.52% |
| 2022 | 80.95 Billion KRW | 89.5% |
| 2021 | 42.72 Billion KRW | -53.38% |
| 2020 | 91.63 Billion KRW | 70.06% |
| 2019 | 53.88 Billion KRW | 27.08% |
| 2018 | 42.39 Billion KRW | -21.2% |
| 2017 | 53.8 Billion KRW | 31.41% |
| 2016 | 40.94 Billion KRW | 704.57% |
| 2015 | -6.77 Billion KRW | -119.27% |
| 2014 | 35.15 Billion KRW | 695.88% |
| 2013 | 4.41 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 53.36 Billion KRW | 108.67% |
| 2024 Q1 | 25.57 Billion KRW | -71.02% |
| 2023 Q3 | 45.59 Billion KRW | 6.49% |
| 2023 Q4 | 88.25 Billion KRW | 93.55% |
| 2023 FY | 212.52 Billion KRW | 162.52% |
| 2023 Q1 | 35.85 Billion KRW | 203.07% |
| 2023 Q2 | 42.81 Billion KRW | 19.43% |
| 2022 Q3 | 28.54 Billion KRW | 23.28% |
| 2022 Q2 | 23.15 Billion KRW | 32.88% |
| 2022 Q1 | 17.42 Billion KRW | 1011.22% |
| 2022 FY | 80.95 Billion KRW | 89.5% |
| 2022 Q4 | 11.82 Billion KRW | -58.56% |
| 2021 Q1 | 15.04 Billion KRW | 34.76% |
| 2021 Q2 | 23.95 Billion KRW | 59.21% |
| 2021 Q3 | 2.14 Billion KRW | -91.05% |
| 2021 Q4 | 1.56 Billion KRW | -26.89% |
| 2021 FY | 42.72 Billion KRW | -53.38% |
| 2020 Q1 | 17.88 Billion KRW | 12.87% |
| 2020 Q3 | 34.94 Billion KRW | 26.44% |
| 2020 Q4 | 11.16 Billion KRW | -68.04% |
| 2020 Q2 | 27.63 Billion KRW | 54.48% |
| 2020 FY | 91.63 Billion KRW | 70.06% |
| 2019 Q2 | 12.66 Billion KRW | 16.65% |
| 2019 FY | 53.88 Billion KRW | 27.08% |
| 2019 Q4 | 15.84 Billion KRW | 9.2% |
| 2019 Q3 | 14.51 Billion KRW | 14.63% |
| 2019 Q1 | 10.85 Billion KRW | -18.35% |
| 2018 Q3 | 13.56 Billion KRW | 6.77% |
| 2018 Q4 | 13.29 Billion KRW | -2.0% |
| 2018 FY | 42.39 Billion KRW | -21.2% |
| 2018 Q2 | 12.7 Billion KRW | 348.7% |
| 2018 Q1 | 2.83 Billion KRW | -80.58% |
| 2017 Q1 | 11.43 Billion KRW | 0.0% |
| 2017 FY | 53.8 Billion KRW | 31.41% |
| 2017 Q2 | 11.22 Billion KRW | -1.86% |
| 2017 Q3 | 16.57 Billion KRW | 47.68% |
| 2017 Q4 | 14.57 Billion KRW | -12.04% |
| 2016 Q1 | 5.56 Billion KRW | 7.98% |
| 2016 Q2 | 7.3 Billion KRW | 31.31% |
| 2016 Q3 | 14.9 Billion KRW | 104.12% |
| 2016 Q4 | - KRW | -100.0% |
| 2016 FY | 40.94 Billion KRW | 704.57% |
| 2015 FY | -6.77 Billion KRW | -119.27% |
| 2015 Q4 | 5.15 Billion KRW | -38.54% |
| 2015 Q3 | 8.38 Billion KRW | 131.73% |
| 2015 Q2 | -26.41 Billion KRW | -532.38% |
| 2015 Q1 | 6.1 Billion KRW | 67.65% |
| 2014 Q1 | 10.84 Billion KRW | 0.0% |
| 2014 FY | 35.15 Billion KRW | 695.88% |
| 2014 Q2 | 11.43 Billion KRW | 5.49% |
| 2014 Q3 | 9.23 Billion KRW | -19.27% |
| 2014 Q4 | 3.64 Billion KRW | -60.53% |
| 2013 FY | 4.41 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 3059.534% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | -266.482% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 456.658% |
| HANDOK Inc. | -28.79 Billion KRW | 837.986% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 2625.448% |
| Yuhan Corporation | 93.5 Billion KRW | -127.272% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -1810.738% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 956.525% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | -45.332% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -5957.137% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 8579.092% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 10347.37% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 4796.769% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -851.611% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 3059.534% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 1114.862% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -5830.758% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 279.692% |
| JW Holdings Corporation | 19.02 Billion KRW | -1016.987% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 369.259% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -474.283% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 470.728% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -3371.57% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -12675.24% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -4146.394% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 3059.534% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -474.917% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | -90.599% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -474.283% |
| Yuhan Corporation | 93.5 Billion KRW | -127.272% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 1407.843% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 5583.648% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -3373.007% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -474.283% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -1024.107% |
| Korea United Pharm Inc. | 48.26 Billion KRW | -340.351% |
| CKD Bio Corp. | -24.19 Billion KRW | 978.458% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -788.58% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -674.542% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -613.773% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 470.728% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | -352.101% |
| Boryung Corporation | 40.2 Billion KRW | -428.623% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 778.339% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 8579.092% |
| JW Lifescience Corporation | 28.14 Billion KRW | -655.122% |